Search

Displaying results 3141 - 3150 of 4262 in total
  1. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.

  2. Drug

    Isaralgagene civaparvovec

    go.drugbank.com/drugs/DB16808
    Investigational

    It is developed by Sangamo Therapeutics and investigated in Fabry Disease.

  3. Drug

    EGT-201

    go.drugbank.com/drugs/DB17648
    Experimental

    Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.[L45939]

  4. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment...

  5. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    Rimexolone is a 1% eye drop solution is a glucocorticoid steroid. It is used to treat inflammation in the eye. It is marketed as Vexol.

  6. Drug

    Dexmedetomidine

    go.drugbank.com/drugs/DB00633
    ApprovedInvestigationalVet approved

    An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

  7. Drug

    Imolamine

    go.drugbank.com/drugs/DB09284
    Investigational

    It is developed under the brand name Coremax by Novartis consumer health SA.

  8. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    The condition targeted by HLX70 in this study is COVID-19.

  9. Drug

    Thalagen

    go.drugbank.com/drugs/DB17714
    Experimental

    Thalagen is a branded product developed by San Rocco Therapeutics.

  10. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    It is being developed by Kalypsys. … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.